Insider Selling Wave Sweeps US Mid-Caps as Executives Trim Into Strength

The wire carried an unusually heavy volume of insider disposition filings. Charles Schwab chief risk officer Nigel Murtagh sold $2.9m of stock, Red Rock Resorts president Scott Kreeger disposed of $1.9m, and Spyre Therapeutics director Albers offloaded $2.4m. Global Industrial saw two separate executives — SVP & CFO Thomas Clark ($684k) and VP & controller Axmacher ($71,332) — sell within the same window, a pattern that typically reflects a coordinated post-earnings trading window opening rather than a single idiosyncratic decision. Smaller sales at Clover Health (CEO Andrew Toy, $408,260) and Slide Insurance (director Stephen Rohde, $105,000) round out the picture. The lone counterweight was AdaptHealth director Kenneth Samet's $149,930 open-market purchase — a modest signal of conviction against an otherwise one-directional flow. Insider selling is a notoriously noisy indicator, driven by tax planning, 10b5-1 scheduling and diversification needs, and should not be read as directional guidance in isolation. But the breadth here — six sellers across four unrelated sectors versus one buyer — is worth flagging for portfolio committees monitoring internal conviction levels as equity indices trade near cycle highs. Capital-markets activity in the same window reinforced the theme of issuers monetising elevated valuations: Silicon Motion priced $1bn of convertible notes and American Healthcare REIT priced a $712m equity offering.